Isolation of a brain peptide identical to the intestinal PHI (peptide HI)  by Tatemoto, Kazuhiko et al.
Volume 153, number 2 FEBS LETTERS March 1983 
Isolation of a brain peptide identical to the intestinal PHI 
(peptide HI) 
Kazuhiko Tatemoto, Mats Carlquist, Thomas J. McDonald+ and Viktor Mutt 
Department of Biochemistry II, Karolinska Institute, S-104 01 Stockholm, Sweden and +Department of Medicine, 
University of Western Ontario, London, Canada 
Received 24 January 1983 
The isolation of a brain peptide identical to the intestinal peptide PHI (peptide HI) is described. The 
peptide was isolated from porcine brain extract using a chemical assay method based on its C-terminal 
isoleucine amide structure. The complete amino acid sequence of the peptide was found to be: His-Ala-- 
Asp-Gly-Val-Phe-Thr-Ser-Asp-Phe-Ser-Arg-Leu-Leu-Gly-Gln-Leu-Ser-Ala-Lys-Lys-Tyr-- 
Leu-Glu-Ser-Leu-Be-NHZ. This sequence is identical to the intestinal peptide thus demonstrating PHI 
to be a brain-gut peptide. The role of PHI in the central nervous system as a neurotransmitter or 
neuromodulator is discussed. 
Brain-gut peptide Neuropeptide Glucagon-secretin family Amino acid sequence 
C-terminal amide 
1. INTRODUCTION 
It has been well recognized that identical pep- 
tides may occur in brain and gut. To date, several 
such peptides have been isolated and shown to be 
identical in both tissues with respect o their amino 
acid sequences. These are: substance P [ 11, 
neurotensin [2], cholecystokinin octapeptide [3], 
somatostatin 28 [4-61, dynorphin [7-81 and the 
hydra head activator [9]. We have also shown that 
a brain peptide is identical to the vasoactive in- 
testinal peptide (VIP) [lo]. 
The intestinal heptacosapeptide PHI (peptide 
HI) was isolated in our laboratory based on its C- 
terminal isoleucine amide structure [ 11,121. Subse- 
Abbreviations: PHI, peptide HI (the peptide having N- 
terminal histidine and C-terminal isoleucine amide); 
VIP, vasoactive intestinal peptide 
A preliminary communication on this study has been 
published: Tatemoto, K. (1983) in: Systematic Role of 
Regulatory Peptides, Symposia Medica Hoechst 18, 
June 1982, in press 
Chemical assay 
quent investigation revealed that it is structurally 
similar to members of the secretin-glucagon fami- 
ly and exhibits biological activities similar to VIP 
[13-171. We reported in [ll] that porcine brain 
contains a peptide with C-terminal isoleucine 
amide and suggested the occurrence of PHI in both 
intestine and brain tissues. We report here the 
isolation of this peptide from porcine brain ex- 
tracts. The amino acid sequence determination in- 
dicates that the brain peptide is indeed identical in 
respect o its amino acid sequence to the PHI of in- 
testinal origin. 
2. MATERIALS AND METHODS 
Isoleucine amide was obtained from Vega 
Biochemicals and dansyl isoleucine amide was 
prepared from isoleucine amide by reaction with 
dansyl chloride [ 181. Dansyl amino acids and 
phenylthiohydantoin amino acids were obtained 
from Calbiochem and Mann Research 
Laboratories, respectively. Dansyl chloride, 
phenylisothiocyanate, pyridine, butyl acetate, 
ethyl acetate, trifluoroacetic acid (TFA) were of se- 
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quanal grade (Pierce Chemical Co.). Polyamide 
thin-layer plates were from Schleicher and Schiill. 
Acetic acid, ethanol and acetonitrile were of spec- 
troscopic or HPLC grade and all other chemicals 
were of analytical grade and were used without 
further purification. 
Peptide HI (PHI) was prepared from porcine in- 
testine as in [12]. The chemical assay for PHI, 
amino acid analysis, N-terminal determination and 
TLC on silica gel layer were performed as in [12]. 
The methods of HPLC for separation of tryptic 
peptide fragments and subsequent microsequence 
analysis by an improved dansyl Edman technique 
were described in [19]. 
3. RESULTS 
3.1. Isolation procedure 
The details of the preparation of the methanol- 
soluble peptide concentrate (the starting material) 
from porcine brain extract were described in 
[10,20]. The methanol-soluble peptide concentrate 
(1.8 g) obtained from 400 kg porcine brain was 
subjected to gel filtration on Sephadex G-25 col- 
umn. The PHI fractions, which also contained 
neuropeptide Y [20] and vasoactive intestinal pep- 
tide [lo], were pooled and lyophilized. The 
lyophilized material (690 mg) was chromatograph- 
ed on CM cellulose column (5 x 20 cm). The pep- 
tide was eluted with 0.01 M ammonium bicar- 
bonate containing 0.025% mercaptoethanol. The 
fraction containing PHI was detected by the 
chemical assay and lyophilized. This procedure 
yielded 38 mg of the fraction containing PHI. The 
fraction was further purified by two successive 
HPLC on a reversed-phase silica gel column, 
PBondapak C-18 (Waters Ass.). The fraction was 
first eluted with 42% ethanol containing 0.2% 
acetic acid and 5 mM ammonium acetate under 
isocratic conditions (fig.1). This HPLC yielded a 
total of 0.8 mg of the lyophilized fractions con- 
taining PHI. The final purification was carried out 
in the second HPLC using a gradient elution 
system: 0.12% TFA/HzO and 0.1% TFAKHKN 
(fig.2). The peptide was found to be eluted in an 
identical position to the intestinal PHI. The pep- 
tide preparation (0.3 mg) was found to be 
homogeneous by amino acid analysis, N- and C- 
terminal determinations and by HPLC and TLC 
analysis. 
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Fig.1. A typical HPLC elution profile of the PHI 
fractions (see text). The PHI fractions (4 mg for each 
run) were applied to a reversed-phase HPLC column 
bBondapak C-18, 7.8 x 300 mm) and eluted with 42% 
ethanol/S mM ammonium acetate/0.2% acetic acid at a 
flow rate of 2 ml/min under isocratic onditions. The 
peak fractions were collected and concentrated to 1/5th 
of the original volumes under reduced pressure. After 
the original volumes were restored by addition of water, 
the fractions were lyophilized and an aliquot of each was 
subjected to the chemical assay. The PHI peak is shown 
in oblique lines. 
3.2. Structural studies 
The results of amino acid analysis revealed that 
the brain peptide had an amino acid composition 
identical to that of the intestinal peptide (table 1). 
The N-terminal residue of the brain peptide was 
determined to be histidine, which is also identical 
to the intestinal PHI [12]. Further structural study, 
using a HPLC tryptic mapping technique, in- 
dicated that treatment of the brain peptide with 
trypsin yielded 5 fragments which were eluted in 
identical positions (fig.3) and had identical amino 
acid compositions (table 1) to the corresponding 
fragments of the intestinal peptide. 
The amino acid sequences of tryptic fragments 
of the peptide were found to be: 
249 
Volume 153, number 2 FEBS LETTERS March 1983 
Fig.2. A HPLC elution profile of the PHI peak (fig.2). 
The PHI fraction (0.4 mg) was rechromatographed on a 
HPLC column (uBondapak C-18, 7.8 x 300 mm) using 
a linear gradient elution system (solvent A; 0.12% 
trifluoroacetic acid/water, solvent B; 0.1% 
trifluoroacetic acid/acetonitrile) at 2 ml/min. The PHI 
fraction (shown in oblique line) was lyophilized as in 
fig.2 and subsequently subjected to amino acid analysis 
and N- and C-terminal determinations. 
Fig.3. HPLC separation of tryptic fragments of brain 
PHI. Trypsin-treated PHI preparation (70 pg) was 
applied to a FBondapak C-18 column (3.9 x 300 mm). 
The tryptic peptides were separated at 1 ml/min using a 
linear gradient system of 0.05% acetic acid and 5 mM 
ammonium acetate (solvent A) and 80% ethanol 
containing 0.04% acetic acid and 5 mM ammonium 
acetate (solvent B, B; O-55% for 30 min). 
Table 1 
Amino acid compositions and NH*-termini of isolated tryptic fragments and whole molecule of brain PHI 
Amino acid T-l T-2 T-3 T-4 T-S Whole molecule 
Ala 
Arg 
Asx 
Glx 
Gly 
His 
Ile 
Leu 
LYS 
Phe 
Ser 
Thr 
TYr 
Val 
1.0 (1) 
1.0 (1) 
2.0 (2) 
1.0 (1) 2.1 (2) 
1.1 (1) 
2.1 (2) 
1.0 (1) 2.1 (2) 
2.1 (2) 
1.0 (1) 
1.0 (1) 1.0 (1) 
2.0 (2) 4.8 (5) 
2.0 (2) 
1.9 (2) 
1.0 (1) 3.8 (4) 
1.0 (1) 
1.0 (1) 1.0 (1) 
1.0 (1) 
1.0 (1) 
1.0 (1) 
1.1 (1) 
1.0 (1) 
1.0 (1) 
1.0 (1) 
2.0 (2) 
1.0 (1) 0.9 (1) 
2.8 (3) 
1.0 (1) 
1.1 (1) 
2.0 (2) 
2.0 (2) 
1.0 (1) 
1.1 (1) 
1.0 (1) 
1.0 (1) 
6 
TYr 
27 
His 
Total residues 
NHZ-terminus 
12 
His 
8 
Leu 
1 7 
LYS LYS 
T-l, His-Ala-Asp-Gly-Val-Phe-Thr-Ser- 
Asp-Phe-Ser-Arg; 
T-2, Leu-Leu-Gly-Gln-Leu-Ser-Ala-Lys; 
T-3, Lys; 
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T-4, Lys-Tyr-Leu-Glu-Ser-Leu-Ile-NHz; 
T-5, Tyr-Leu-Glu-Ser-Leu-Ile-NH*. 
Thus the complete amino acid sequence of the 
brain peptide should be: 
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His-Ala-Asp-Gly-Val-Phe-Thr-Ser-Asp-Phe-Ser-Arg-LeU~Leu- 
_~ ~~_~ __ ._...~ T-J ~~-~ _--d c- - 
anterior pituitary [23]. Since PHI is present abun- 
dantly in the brain, this peptide may indeed have 
its role as a neurotransmitter or neuromoduiator in 
the central nervous system. 
Gly_G~n-Le~~S~r.Ala-Lys-Lys-Tyr.Leu-Glu-Ser~LeU~ll~~NH~ ACKNOWLEDGEMENTS 
-.. -T-4- -+ 
Fig.4. The amino acid sequence of brain PHI. The 
sequence of PHI was determined after separation of the 
tryptic fragments (T-l-T-5 in table 1) by HPLC using a 
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